Advanced search
Publication Cover
International Journal of Neuroscience Volume 126, 2016 - Issue 8
Submit an article Journal homepage
716
Views
9
CrossRef citations to date
0
Altmetric
Reviews

Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke

Lingling ZhangDepartment of Neurology, Clinical Medical College, Yangzhou University, Yangzhou, Jiangsu225001, China
,
Kangping SongDepartment of Neurology, Clinical Medical College, Yangzhou University, Yangzhou, Jiangsu225001, China
,
Mengting ZhuDepartment of Neurology, Clinical Medical College, Yangzhou University, Yangzhou, Jiangsu225001, China
,
Jinling ShiDepartment of Neurology, Clinical Medical College, Yangzhou University, Yangzhou, Jiangsu225001, China
,
Huijuan ZhangDepartment of Neurology, Clinical Medical College, Yangzhou University, Yangzhou, Jiangsu225001, China
,
Liang XuDepartment of Neurology, Clinical Medical College, Yangzhou University, Yangzhou, Jiangsu225001, China
&
Yingzhu ChenDepartment of Neurology, Clinical Medical College, Yangzhou University, Yangzhou, Jiangsu225001, ChinaCorrespondence[email protected]
 show all
Pages 675-680 | Received 10 Nov 2014, Accepted 28 May 2015, Published online: 14 Jul 2015

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Larysa Strilchuk, Federica Fogacci & Arrigo Fg Cicero. (2019) Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data. Expert Opinion on Drug Safety 18:7, pages 611-621.
Read now
Vybhav Jetty, Charles J Glueck, Kevin Lee, Naila Goldenberg, Marloe Prince, Ashwin Kumar, Michael Goldenberg, Ishan Anand & Ping Wang. (2017) Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy. Vascular Health and Risk Management 13, pages 247-253.
Read now

Articles from other publishers (7)

Olena Fedotkina, Ruchi Jain, Rashmi B. Prasad, Andrea Luk, Marta García-Ramírez, Türküler Özgümüs, Liubov Cherviakova, Nadiya Khalimon, Tetiana Svietleisha, Tetiana Buldenko, Victor Kravchenko, Deepak Jain, Allan Vaag, Juliana Chan, Mykola D. Khalangot, Cristina Hernández, Peter M. Nilsson, Rafael Simo, Isabella Artner & Valeriya Lyssenko. (2022) Neuronal Dysfunction Is Linked to the Famine-Associated Risk of Proliferative Retinopathy in Patients With Type 2 Diabetes. Frontiers in Neuroscience 16.
Crossref
Stefan Toth, Dominik Pella & Jan Fedacko. (2020) Vaccines Targeting PSCK9 for the Treatment of Hyperlipidemia. Cardiology and Therapy 9:2, pages 323-332.
Crossref
Nevena Veljkovic, Bozidarka Zaric, Ilona Djuric, Milan Obradovic, Emina Sudar-Milovanovic, Djordje Radak & Esma R. Isenovic. (2018) Genetic Markers for Coronary Artery Disease. Medicina 54:3, pages 36.
Crossref
Carmen Lammi, Chiara Zanoni, Simonetta Ferruzza, Giulia Ranaldi, Yula Sambuy & Anna Arnoldi. (2016) Hypocholesterolaemic Activity of Lupin Peptides: Investigation on the Crosstalk between Human Enterocytes and Hepatocytes Using a Co-Culture System Including Caco-2 and HepG2 Cells. Nutrients 8:7, pages 437.
Crossref
Carmen Lammi, Chiara Zanoni, Laura Calabresi & Anna Arnoldi. (2016) Lupin protein exerts cholesterol-lowering effects targeting PCSK9: From clinical evidences to elucidation of the in vitro molecular mechanism using HepG2 cells. Journal of Functional Foods 23, pages 230-240.
Crossref
Anthony Au, Lyn R. Griffiths, Kian-Kai Cheng, Cheah Wee Kooi, Looi Irene & Loo Keat Wei. (2015) The Influence of OLR1 and PCSK9 Gene Polymorphisms on Ischemic Stroke: Evidence from a Meta-Analysis. Scientific Reports 5:1.
Crossref
Gaojun Cai, Bifeng Zhang, Ganwei Shi, Weijin Weng, Chunyan Ma, Yanbin Song & Ji Zhang. (2015) The associations between proprotein convertase subtilisin/kexin type 9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels: a meta-analysis. Lipids in Health and Disease 14:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.